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Addendum
Subsequent to the writing of this editorial, I
was contacted by the president of Estech,
Inc. I was pleased to learn that Estech has
enacted a new policy regarding disclosure
of relationships that others might interpret
as conflicts of interest. Specifically, I be-
lieve they have set a high watermark for
industry: Their new consulting agreements
require disclosure of this relationship on
material that their consultants submit for
publication or presentation; failure of the
consultant to so indicate the relationship is
grounds for nonpayment of either honoraria
or grants. It is gratifying to see the conflict
of interest issue being addressed in such ay
proactive fashion.n recent weeks, your Editor became involved in a lengthy series of E-mails and
telephone conversations with a reporter from The Wall Street Journal. It seems
that three articles were published by us in which the authors had clear conflicts
f interest (COI) that we did not report. In one case, we failed to transmit potential
onflicts disclosed by the authors. In the other two instances, my interpretation is
hat serious potential COIs were withheld from the Journal at the time of submis-
ion. One author had an important financial relationship with AtriCure (Cincinnati,
hio) that he chose not to disclose. In the other instance, far more complex
elationships existed that ranged from consulting agreements by some authors to
uthors having control over financial investments that might have profited from
ncreased value of AtriCure stock. Both articles, regardless of how egregious the
iolations of our policy, survived careful peer review and generated work deemed
eritorious.
As a result of this experience, I was forced to reconsider the Journal’s COI policy
nd refresh my own knowledge of the issue. It is not my purpose in this editorial to
xplore the many facets of the COI controversy because the issue has been discussed
t length by scientists, ethicists, politicians, national medical leaders, and the press.
he evidence seems pretty strong to me that important financial interests in the
utcomes and interpretations of studies can influence those interpretations. For the time
eing, I do not subscribe to the philosophy that these conflicts invalidate the work. I do,
owever, believe that reviewers and readers have a right to be forewarned that a
otential bias might exist. I also believe that determination of whether or not a
onflict exists should not be in the hands of the potentially conflicted.
Richard Smith, former Editor of the BMJ (British Medical Journal), has written
houghtfully on this topic. I like his conclusive statement that “conflict of interest is a
ondition not a behaviour.” That being the case, asking an author to determine whether
he had a COI is analogous to the adage that “a doctor who treats himself has a fool for
doctor.” We do not ask authors to manage their COI nor to declare one. We ask only
hat they disclose to us all their relationships with industry and those of their coauthors.
e accept the responsibility for using those disclosures to unveil a potential COI; that
s, we use the objective disclosures to make a diagnosis and, as a remedy, we publish the
xistence of a relationship that could be construed as a COI.
My editorial staff, associate editors, reviewers, and editorial board members are
ot police officers. We assume that authors are inherently honest and forthcoming
ith required information. We assume that their institutions have policies that
anage COI before research, human or otherwise, is allowed. What we have never
one is to punish authors who violate our disclosure policies, and I was astonished
o learn that no systematic penalties exist for such devious behavior. Thus, at its last
ouncil meeting, The American Association for Thoracic Surgery agreed with a
roposal from me to deny authors who violate our disclosure policy the privilege of
ublishing their work in our Journal for some period of time, probably one to two
ears. This solution is not perfect but it is practical. In some instances, we will be










































Lunishing our readers as much as sneaky authors. I think,
owever, that the message is clear: We take disclosure of
elationships that might influence article content very
eriously.
As does every student of the issue of COI, I know that
his approach is not enough. What about our reviewers? Are
hey in competition with the author of an article they re-
iew? Does personal animosity exist? Is there potential gain
o the reviewer by looking favorably on certain work? How
an a pragmatic approach to running the Journal be bal-
nced with these incredibly complex issues?
I have decided to make two important changes in Journal
olicy to try to manage these issues. First, we will ask all
eviewers that which we should not ask of them: “Does this
rticle in any way raise the potential of a conflict of interest?”
e are also going to incorrectly allow the reviewer to manage
hat potential conflict by stating that he or she does not believe
ny potential conflict prohibits him or her from providing a
ood, scientifically valid review. Ultimately, all reviews are
udged by me and my associate editors in the context of other
eviews and of our own impressions of the submitted work.
Second, and more important, we have established a for-of Atricure, is paid by the hour and worked a total o
72 The Journal of Thoracic and Cardiovascular Surgery ● Apriditor, Dr Martin McKneally, we are convening a panel
hose members will review the disclosures of all authors as
hey relate to any article accepted for publication. When the
thics panel believes a conflict exists, we will publish the
isclosures of the authors.
Finally, we must acknowledge that every system remains
t the mercy of our authors and of our belief in the inherent
onesty and desire to “do the right thing” that has been a
allmark of our profession and specialty over the years. We
ssert the belief that our authors are persons of character and
ccept the notion that character is doing the right thing when
o one is looking. If an author offends us by displaying a
ack of character, we believe our disciplinary action is
ppropriate.
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Notices of Correction
In the June 2005 issue of the Journal, the article by Dr. Gillinov and associates titled “Surgical
ablation of atrial fibrillation with bipolar radiofrequency as the primary modality” (2005;129:1322-9)
contained incomplete disclosure statements. Dr. Gillinov provided the following additional informa-
tion: Drs. McCarthy and Gillinov were consultants to Atricure, Inc when the manuscript was written.
Dr. Gillinov has no equity interest in Atricure, Inc. At the time of manuscript submission, Dr.
McCarthy did not have an equity interest in Atricure, Inc. Dr. Cosgrove previously served on the
Board of Directors of Atricure, Inc. The Cleveland Clinic has an interest in a venture capital fund
which has an investment in Atricure, Inc.
In the October 2004 issue of the Journal, pursuant to the article by Dr. Gaynor and associates titled
“A prospective, single-center clinical trial of a modified Cox maze procedure with bipolar radiofre-
quency ablation” (2004;128:535-42), the authors disclosed to the Journal that Dr. Schuessler and Dr.
Damiano were consultants to Atricure, Inc. The Journal did not include this information with the
article. In a follow-up inquiry, Dr. Damiano indicated that his disclosure and that of Dr. Schuessler
were complete and that neither had stock ownership, equity interest, or patient license arrangements
with Atricure.
In the September 2005 issue of the Journal, pursuant to the article by Dr. Wolf and associates titled
“Video-assisted bilateral pulmonary vein isolation and left atrial appendage exclusion for atrial
fibrillation” (2005;130:797-802), the authors disclosed in their initial cover letter to the Journal only
that Drs. Schneeberger, Gillinov and Wolf received educational grants from Atricure that were not
used to fund this research. In a follow-up response to further inquiry, Dr. Wolf disclosed the following
information: He was, at the time of manuscript submission, a consultant to Atricure and had equity
interests in the form of option shares and warrants that were less than 0.5% ownership of the company.
Dr. Gillinov was a consultant to Atricure in November of 2004. Dr. Schneeberger was a consultant in
November of 2004 and had equity interests consisting of option shares in the company that were less
than 0.5% ownership of the company. Dr. Flege is a member of the Event Adjudication Committeef one hour during the last 2 years.
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